LEXICON PHARMACEUTICALS, INC. Inventory, Finished Goods, Net of Reserves
LEXICON PHARMACEUTICALS, INC. (LXRX) had Inventory, Finished Goods, Net of Reserves of $128.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2025-03-07
- 2024-12-31: Inventory, Finished Goods, Net of Reserves $128.00K.
- 2024-09-30: Inventory, Finished Goods, Net of Reserves $450.00K.
- 2024-06-30: Inventory, Finished Goods, Net of Reserves $399.00K.
- 2024-03-31: Inventory, Finished Goods, Net of Reserves $430.00K.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2024-12-31 | $128.00K 10-K · filed 2025-03-07 |
| 2024-09-30 | $450.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $399.00K 10-Q · filed 2024-08-02 |
| 2024-03-31 | $430.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $281.00K 10-K · filed 2025-03-07 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-25 |
| 2020-06-30 | $650.00K 10-Q · filed 2020-07-29 |
| 2020-03-31 | $812.00K 10-Q · filed 2020-04-27 |
| 2019-09-30 | $1.09M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $324.00K 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |